Neurocrine Not Giving Up On Luvadaxistat Despite Phase II Miss

 
• By Joseph Haas

Schizophrenia drug licensed from Takeda missed Phase II endpoint for negative symptoms, but hits secondary cognition endpoints. Neurocrine plans to further study compound for cognitive benefits.

Schizophrenia
Despite disappointing data, Neurocrine thinks its schizophrenia drug could offer cognitive benefit

More from Clinical Trials

More from R&D